OPEN END-TURBO-OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time BOERSE MUENCHEN 01:37:22 2024-07-03 pm EDT | ||
| 2.48 EUR | +19.81% |
|
| Current month | +0.49% | ||
| 1 month | -25.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 2.48 | +19.81% |
| 24-07-02 | 2.07 | +13.74% |
| 24-07-01 | 1.82 | -11.65% |
| 24-06-28 | 2.06 | +5.64% |
| 24-06-27 | 1.95 | -2.50% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 01:37 pm EDT
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | HSBC |
| WKN | HS4QGN |
| ISIN | DE000HS4QGN8 |
| Date issued | 2024-02-08 |
| Strike | 163.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.43 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.28 € |
|---|---|
| Lowest since issue | 1.63 € |
| Spread | 0.07 € |
| Spread % | 2.82% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
